Adalyon | Optimising clinical trials using speech biomarkers

“The Scius team efficiently helped us to raise our international profile as having an innovative approach using biomarkers from speech to optimise clinical trials. They refined our corporate messaging, delivered quality media coverage, and raised our visibility by securing high-profile speaker slots at major life sciences partnering events.”

Ulrik Tirsted Zeuthen
CEO of Adalyon

Objectives

Raise awareness of the company’s novel patient-centric approach to using speech biomarkers to accelerate clinical decision making by capturing better data through reducing patient burden
Highlight the company’s recent milestones including appointment of new CEO
Secure visibility at major partnering events
Post regularly on LinkedIn to build audience and create engagement

Strategy

Developed an original ‘tag-line’: “Speech is the new blood” to simplify the offering
Pitched the company to event program managers for a speaker panel as one-to-watch in tech-bio.
Media relations around an appointment press release
Enhanced the content of the corporate deck for use in partnering meetings
Provided on the ground support at leading industry events, including filming the CEO at BIO-Europe Spring

Results

Speaker slot on an LSX World Congress Europe panel about improving clinical trials, which Scius wrote up and was published on the widely read Informa Connect platform
Coverage in trade media, including a podcast interview of the CEO and the CSO
Engaging LinkedIn posts, including video from BIO-Europe Spring
Enhanced company’s visibility with pharma and other core targets including University hospitals